Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease
- 246 Downloads
Aspirin has been the cornerstone of therapy for the secondary prevention treatment of patients with cardiovascular disease since landmark trials were completed in the late 1970s and early 1980s that demonstrated the efficacy of aspirin for reducing the risk of ischemic events. Notwithstanding the consistent benefits demonstrated with aspirin for both acute and chronic cardiovascular disease, there are a number of toxicities associated with aspirin that have been showcased by recent long-term clinical trials that have included an aspirin monotherapy arm. As an inhibitor of cyclooxygenase (COX), aspirin impairs gastric mucosal protective mechanisms. Previous trials have shown that up to 15–20 % of patients developed gastrointestinal symptoms with aspirin monotherapy, and approximately 1 % of patients per year had a clinically significant bleeding event, including 1 in 1000 patients who suffered an intracranial or fatal bleed. These risks have been shown to be compounded for patients with acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI) who are also treated with other antithrombotic agents during the acute care/procedural period, as well as for an extended time period afterwards. Given observations of substantial increases in bleeding rates from many prior long-term clinical trials that have evaluated aspirin together with other oral platelet inhibitors or oral anticoagulants, the focus of contemporary research has pivoted towards tailored antithrombotic regimens that attempt to either shorten the duration of exposure to aspirin or replace aspirin with an alternative antithrombotic agent. While these shifts are occurring, the safety profile of aspirin when used for the secondary prevention treatment of patients with established cardiovascular disease deserves further consideration.
KeywordsAspirin Percutaneous Coronary Intervention Clopidogrel Ticagrelor DAPT
Compliance with Ethical Standards
No sources of funding were used to assist in the preparation of this study.
Conflict of interest
Alexander Fanaroff has no conflicts of interest that are directly related to the content of this manuscript. Matthew Roe reports receiving research funding from Eli Lilly, Sanofi–Aventis, Daiichi Sanko, Janssen Pharmaceuticals, Ferring Pharmaceuticals, American College of Cardiology, American Heart Association, and the Familial Hypercholesterolemia Foundation; and reports receiving consulting fees or honoraria from PriMed, Astra Zeneca, Boehringer–Ingelheim, Merck, Amgen, Myokardia, Eli Lilly, and Elsevier Publishers.
- 1.Blackwell DL, Lucas J, Clarke TC. Summary health statistics for U.S. adults: National Health Interview Survey, 2012. Vital Health Stat. 2014;10(260):1–161.Google Scholar
- 7.Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Douglas PS, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44–164.CrossRefPubMedGoogle Scholar
- 10.U.S. Preventive Service Task Force. Draft recommendation statement: aspirin to prevent cardiovascular disease and cancer. September 2015. Available at: http://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/aspirin-to-prevent-cardiovascular-disease-and-cancer. Accessed 3 Sept 2016.
- 11.Amsterdam E, Wenger N. 2014 ACC/AHA guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: executive summary. J Am Coll Cardiol. 2014;64:2645–87.CrossRefGoogle Scholar
- 12.O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78–140.CrossRefPubMedGoogle Scholar
- 13.Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.CrossRefPubMedGoogle Scholar
- 16.Bayer. Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS). [Clinicaltrials.gov identifier NCT01776424]. US National Institutes of Health, ClinicalTrials.gov. Available at: https://clinicaltrials.gov/show/NCT01776424. Accessed 10 Mar 2016.
- 17.Vranckx P, Valgimigli M, Windecker S, Steg P, Hamm C, Jüni P, et al. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention. 2015;11(7).Google Scholar
- 18.Janssen Research & Development LLC. A study to compare the safety of rivaroxaban versus acetylsalicylic acid in addition to either clopidogrel or ticagrelor therapy in participants with acute coronary syndrome (GEMINI ACS 1). [ClinicalTrials.gov identifier NCT02293395]. US National Institutes of Health, Clinicaltrials.gov. Available at: https://clinicaltrials.gov/show/NCT02293395. Accessed 10 Mar 2016.
- 19.Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Amn Heart J. 2015;169(4):472–8.e5.Google Scholar
- 20.Boehringer Ingelheim. Evaluation of dual therapy with dabigatran vs. triple therapy with warfarin in patients with AF that undergo a PCI with stenting (REDUAL-PCI). [ClinicalTrials.gov identifier NCT02164864]. US National Institutes of Health, ClinicalTrials.gov. Available at: https://clinicaltrials.gov/show/NCT02164864. Accessed 10 Mar 2016.
- 21.Bristol-Myers Squibb. Study apixaban to vitamin K antagonist for the prevention of stroke or systemic embolism and bleeding in patients with non-valvular atrial fibrillation and acute coronary syndrome/percutaneous coronary intervention [ClinicalTrials.gov identifier NCT02415400. US National Institutes of Health, Clinicaltrials.gov. Available at: https://clinicaltrials.gov/show/NCT02415400. Accessed 10 Mar 2016.
- 24.Topper JN, Cai J, Falb D, Gimbrone MA. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci. 1996;93(19):10417–22.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906–13.CrossRefPubMedGoogle Scholar
- 42.Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676–81.e1.Google Scholar
- 45.Córdoba-Soriano JG, Corbí-Pascual M, López-Neyra I, Navarro-Cuartero J, Hidalgo-Olivares V, Barrionuevo-Sánchez MI, et al. Early aspirin desensitization in unstable patients with acute coronary syndrome: short and long-term efficacy and safety. Eur Heart J Acute Cardiovasc Care 2015 (Epub 20 Nov 2015:2048872615618509).Google Scholar
- 48.Aspirin in coronary heart disease. The Coronary Drug Project Research Group. J Chronic Dis. 1976;29(10):625–42.Google Scholar
- 51.Breddin K, Loew D, Lechner K, Oberla K, Walter E. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group. Circulation. 1980;62(6 Pt 2):V63–72.Google Scholar
- 54.Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Lancet. 1997;350(9075):389–96.Google Scholar
- 55.Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation. 2002;105(5):557–63.CrossRefPubMedGoogle Scholar
- 59.Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet. 2000;355(9201):337–45.Google Scholar
- 65.Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48(12):2584–91.CrossRefPubMedGoogle Scholar
- 66.Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44–122.CrossRefPubMedGoogle Scholar
- 67.Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541–619.CrossRefPubMedGoogle Scholar
- 69.Savage MP, Goldberg S, Bove AA, Deutsch E, Vetrovec G, Macdonald RG, et al. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty: multi-hospital eastern atlantic restenosis trial (M-HEART II). Circulation. 1995;92(11):3194–200.CrossRefPubMedGoogle Scholar
- 70.Serruys PW, Rutsch W, Heyndrickx GR, Danchin N, Mast E, Wijns W, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). Circulation. 1991;84(4):1568–80.CrossRefPubMedGoogle Scholar
- 72.Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman J-P, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107–15.CrossRefPubMedGoogle Scholar